GlassScriptPhysician profile
Latangela Smith
NPI 1790162493
$3,296.41
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $638 · 2021: $1,767 · 2022: $540 · 2023: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $693.83 | 2020-2023 | |
| Ucb, INC. | $357.21 | 2019-2023 | Nayzilam |
| Allergan, INC. | $282.58 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $268.76 | 2020-2023 | Austedo |
| Sk Life Science, INC. | $247.06 | 2020-2021 | |
| Abbvie INC. | $166.28 | 2021-2023 | Botox, Ubrelvy |
| Livanova USA, INC. | $132.58 | 2020-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $127.76 | 2021-2022 | |
| Genentech USA, INC. | $127.29 | 2021-2022 | |
| Emd Serono, INC. | $85.95 | 2021-2022 | |
| Eisai INC. | $84.55 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $83.45 | 2020-2021 | |
| Lundbeck LLC | $81.23 | 2020-2021 | |
| Lilly USA, LLC | $76.85 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $71.13 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $70.19 | 2021 | |
| Kyowa Kirin, INC. | $50.66 | 2021 | |
| Amneal Pharmaceuticals LLC | $44.54 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $31.24 | 2023 | Epidiolex |
| Genzyme Corporation | $27.17 | 2022 | |
| Grt US Holding, INC. | $21.36 | 2021 | |
| Merz Pharmaceuticals, LLC | $20.87 | 2023 | Xeomin |
| Mdd US Operations, LLC | $17.80 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.35 | 2022 | |
| Adamas Pharmaceuticals, INC. | $16.33 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.81 | 2021 | |
| Sumitomo Pharma America, INC. | $14.98 | 2023 | Aptiom |
| Zogenix INC. | $13.74 | 2021 | |
| Neurocrine Biosciences, INC. | $13.01 | 2021 | |
| Biogen, INC. | $12.35 | 2022 | |
| Neurelis, INC. | $11.92 | 2021 | |
| Amgen INC. | $11.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latangela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.